Drugs / ABL501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05101109 | Oct 2021 → May 2024 | neoplasm | ABL Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABL501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05101109 ↗ |
| Action | Inhibit | “ABL501 that efficiently inhibits both LAG-3 and PD-L1 pathways” PMID 35526096 ↗ May 2022 |